BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27443637)

  • 1. Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer.
    Wong AT; Schwartz D; Osborn V; Safdieh J; Weiner J; Schreiber D
    Urol Oncol; 2016 Dec; 34(12):529.e15-529.e20. PubMed ID: 27443637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    Moschini M; Sharma V; Gandaglia G; Dell'Oglio P; Fossati N; Zaffuto E; Montorsi F; Briganti A; Karnes RJ
    BJU Int; 2017 Jul; 120(1):69-75. PubMed ID: 27753192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
    Briganti A; Karnes RJ; Da Pozzo LF; Cozzarini C; Capitanio U; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Di Muzio N; Rigatti P; Montorsi F; Blute M
    Eur Urol; 2011 May; 59(5):832-40. PubMed ID: 21354694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
    Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
    BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
    Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
    Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.
    Zincke H; Bergstralh EJ; Larson-Keller JJ; Farrow GM; Myers RP; Lieber MM; Barrett DM; Rife CC; Gonchoroff NJ
    Cancer; 1992 Jul; 70(1 Suppl):311-23. PubMed ID: 1600493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes in Men Undergoing Radical Prostatectomy After Primary Radiation Treatment for Adenocarcinoma of the Prostate.
    Pokala N; Huynh DL; Henderson AA; Johans C
    Clin Genitourin Cancer; 2016 Jun; 14(3):218-25. PubMed ID: 26774347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
    Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.
    Wiegel T; Bartkowiak D; Bottke D; Bronner C; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Stöckle M; Rübe C; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hofmann R; Engenhart-Cabillic R; Hinke A; Hinkelbein W; Miller K
    Eur Urol; 2014 Aug; 66(2):243-50. PubMed ID: 24680359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
    Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
    Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Vizziello D; Sun M; Karakiewicz PI; Menon M; Montorsi F; Briganti A
    J Clin Oncol; 2014 Dec; 32(35):3939-47. PubMed ID: 25245445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.